CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Curious about which cash back credit cards don't charge an annual fee? Discover options that allow you to earn rewards without extra costs.
26,317 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
AeroVironment stock climbed today after a major government contract announcement. This article breaks down what happe...
The Dow’s first-half drama centered on one tech mega-cap that stood out for all the wrong reasons. This article break...
Memory plays a critical role in AI growth, and micron's data center gross margin has surged to industry-leading level...
Geopolitics just accelerated volatility in energy markets. The rejection of a ceasefire proposal by iran has traders ...
FedEx recently spun off its FedEx Freight unit, creating two focused companies. This article explains what that move ...
Adobe Stock sits at a crossroads as the company leans into AI, subscriptions, and enterprise workflows. This guide ex...
Snow-season demand shapes profitability for snow equipment makers. This article breaks down douglas dynamics (plow) e...
Investors eye defense names as budget cycles shape returns. This guide compares Lockheed Martin and RTX, breaking dow...
The AI boom has put semiconductors in the spotlight. This guide breaks down the AMD vs Intel debate, offering a clear...
Finding value in semiconductors is tough, but a disciplined approach can spot opportunities amid rapid tech change. L...
Alphabet ramps up AI-enabled cloud expansion and heavy spending, fueling the debate over whether it can become the ne...